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As there is an urgent need for careful planning of development schemes for new classes of
molecularly targeted anticancer therapies, the use of biomarkers as surrogate endpoints in
therapeutic trials was discussed by BDA delegates, representing the pharmaceutical indus-
try, regulatory agencies, academia, and patient advocacy groups in a breakout session. The
aim was the clarification of the role of surrogates in the conduct of clinical trials that serve
as a basis for drug licensure or registration, especially in the setting of accelerated or con-
ditional approval. The discussions focused on three questions: (a) how to validate biomark-
ers, (b) how biomarkers might be used as surrogate endpoints in small clinical trials, and (c)
how a biomarker might be used in studies of agents other than the one for which it was
validated. The deliberations of the group are discussed herein.
 2007 Elsevier Ltd. All rights reserved.1. Biomarkers as regulatory tools targeted anticancer therapies.3 Hence, biomarkers play anAs there is an urgent need for careful planning of develop-
ment schemes for new classes of molecularly targeted anti-
cancer therapies, the use of biomarkers as surrogate
endpoints in therapeutic trials was discussed by BDA dele-
gates, representing the pharmaceutical industry, regulatory
agencies, academia, and patient advocacy groups in a break-
out session. The aim was the clarification of the role of surro-
gates in the conduct of clinical trials that serve as a basis for
drug licensure or registration, especially in the setting of
accelerated or conditional approval.
Biomarkers are characteristics that are objectively mea-
sured and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses to
a therapeutic intervention.1,2 Biomarkers have assumed an
increasingly important role as surrogate endpoints in the
development and approval of new molecularly targeted anti-
cancer agents. Biomarkers have been the impetus in the shift
away from the ‘one size fits all’ and toward ‘the right drug at
the right dose in the right patient’ approach for molecularlyer Ltd. All rights reserved
de (M.E. Scheulen).important role for scientists and industry in drug develop-
ment and also for regulators in the licensure or registration
process who expect changes induced in a surrogate endpoint
by a therapy to reflect changes in a clinically meaningful end-
point, such as survival.
In the context of clinical trials, biomarkers are usually
pharmacologic markers that can serve as a surrogate marker
or surrogate endpoint., According to Robert Temple of the U.S.
Food and Drug Administration, ‘a surrogate endpoint of a
clinical trial is a laboratory measurement or physical sign
used as a substitute for a clinically meaningful endpoint that
measures directly how a patient feels, functions, or survives.
Changes induced by a therapy are expected to reflect changes
of a clinically meaningful endpoint.4
Use of surrogates entails certain advantages and disadvan-
tages. Generally speaking, clinical trials that rely on surrogate
endpoints can be faster, cheaper, and more efficient than
those with clinical endpoints, but it is critical to bear in
mind that surrogates are not a measure of the endpoint of
real interest. An additional drawback is that reliance on a.
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trolled safety data than would be obtained from a trial with a
clinically relevant endpoint.5
Regulators in the United States and the European Union
emphasise that if biomarkers are to be used as regulatory
tools, they must be validated, be consistent with the patho-
physiology of the disease, and have some biological plausibil-
ity. Regulators give credence to epidemiologic evidence that a
biomarker is a risk factor for the disease under study as well
as confirmation that it is on the intervention pathway. Effects
of treatment on the biomarker should explain or be associ-
ated with the effects of treatment on the clinical endpoint.
Establishing that a biomarker possesses such characteristics
bolsters the case for relying on it for accelerated (United
States) or conditional (European Union) approval.
2. Questions that must be considered
The BDA has a strong interest in the identification and use of
surrogates in improving the cancer drug development pro-
cess. Exploration using biomarkers has several aims. They al-
low the drug to be followed until it reaches the target and
enable its effects at the tumour site to be identified. Such
markers can also help define subpopulations of patients
who would be most likely to benefit from a particular therapy,
thereby minimising the numbers of patients exposed to the
risk of treatment with little likelihood of clinical benefit.6
Therefore, investigators, industry, and regulators must find
common ground when designing safety and efficacy trials of
molecularly targeted agents, in order to conduct trials in the
most expeditious way to deliver effective therapies to market
as quickly as possible.
Questions remain, however, about the use of biomarkers
as surrogates in clinical trials. The BDA delegates discussed
three in particular during the breakout session:
1. Are there situations when novel, unvalidated biomarkers
can be considered as primary supportive evidence (e.g.,
surrogate endpoints) for regulatory approval?
2. Following validation of a biomarker based on a traditional
endpoint (e.g., survival), could a biomarker be used as an
endpoint for registration (conditional/accelerated) for
another compound, most likely in the same tumour type
and setting? [The original version used ‘initial proof of cor-
relation’ rather than ‘validation’, but the participants
seemed to agree that ‘validation’ was better.]
3. Could a biomarker be used as an endpoint for conditional
registration (EU) or accelerated approval (US) in the case of
a rare indication where clinical benefit cannot be demon-
strated formally in a randomised, controlled trial?
The above questions served as a framework for the BDA
delegates’ discussion of surrogates, discussed in the sections
that follow.
3. Exploring a role for unvalidated biomarkers
in regulatory approval
From the current regulatory perspective, unvalidated
biomarkers have little or no role in the approval process.However, complete validation is not always realistic or possi-
ble. Under such circumstances, extrapolation would be re-
quired with acceptance of some degree of uncertainty.
Depending on the setting, similarity of background evidence,
robustness and size of the results, such data could be used as
supportive evidence for a regulatory filing.
4. Using a surrogate in studies of other
compounds
If, for example, a surrogate endpoint (validated biomarker)
were used as a basis for approving a particular tyrosine kinase
inhibitor for treating chronic myelocytic leukaemia, would
regulators accept that same surrogate for approving a novel
tyrosine kinase inhibitor to be used for the same indication?
The regulatory view holds that correlation is not the same
as validation. Correlation would not be considered a sufficient
criterion for establishing a biomarker as a surrogate for clini-
cal benefit, usually defined as overall survival. Initial proof of
correlation, however, could be the first step in validation, but
validation of a biomarker is critical to regulators considering
accelerated or conditional approval of an anticancer agent.
Biomarkers could be used to support the case for approval
even if they are not formally validated; for example, some sur-
rogates are actually part of the disease definition and contrib-
ute directly to the clinical outcomes of those patients.
Nevertheless, caution must be exercised because biomarkers
do not always correlate with clinical benefit.
One challenge arises because pinpointing when everyone
would agree that a biomarker is valid and could then use it
confidently is not possible. Although it would be useful to
be able to define the point when a drug might receive condi-
tional/accelerated approval based on a surrogate validated for
another therapy, the situation is unfortunately not so clear.
The price for early approval based on surrogates is greater
uncertainty. Consider the hypothetical example of a biologi-
cally plausible marker used as a surrogate endpoint in several
studies with different compounds. The surrogate endpoint
correlatedwell with the outcomes in each trial. In such a case,
no one could object to using the biomarker again. On the
other hand, if only one or two studies have been done using
a biomarker as the surrogate endpoint, and it showed some,
but not compelling, correspondence with clinical outcomes,
chances are the regulatory authority would not accept that
biomarker as a surrogate endpoint for another agent. The le-
vel of uncertainty that would be acceptable depends on a
number of factors. For example, why rely on progression-free
survival (a surrogate) if death (a clinical outcome) occurs a
few weeks after disease progression. In this situation, regula-
tors would have no reason to accept progression-free survival
as a basis for approval of the agent.
Mode of action is another important consideration that
could make it difficult to use even a validated biomarker as
a basis for approval of another compound. For example, con-
sider the reliance upon blood cholesterol as a surrogate for
cardiovascular risk. Hormone replacement therapy reduces
cholesterol, but it does not reduce cardiovascular risk; in fact,
it appears to increase risk. Another example would be gastro-
intestinal stromal tumour (GIST) with hepatic metastases
that, treated with imatinib (Gleevec/Glivec), demonstrate
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raphy (PET) signal, but little if any change in their size
(Fig. 1). Such findings cast doubt on some criteria used to indi-
cate tumour response and define remission.
5. Role for surrogates in small clinical trials
For rare diseases, standard clinical endpoints might not be
appropriate. Because of the small populations affected, tradi-
tional endpoints would not be achieved in a practicable time
frame. Also, as is the case in some neoplasms that involve
rare translocations, a biomarker might have a strong biologi-
cal rationale, but a formal, true validation might never be
achieved because of the small number of patients.
The European Medicines Agency (EMEA) issued a draft
guideline7 that takes into consideration the practical difficul-
ties of clinical research in small populations and offers a
ranked hierarchy of evidence that can serve to support an
application:
1. Meta-analyses of good-quality, randomised, controlled
clinical trials that all show consistent results.
2. Individual randomised, controlled trials.
3. Meta-analyses of observational studies.
4. Individual observational studies.Fig. 1 – Magnetic resonance imaging (upper) and PET studies (lo
images on the left represent pretreatment baseline studies and
therapy. The PET scans show nearly complete resolution of the
study. Courtesy of M. E. Scheulen, Innere Universita¨tsklinik (Tu5. Published case reports.
6. Anecdotal case reports.
7. Opinion of experts in the field.
In addition, EMEA acknowledges that detailed knowledge
of the pathophysiology of the disease and the pharmacology
of the drug will facilitate the design of efficient clinical stud-
ies and help determine the amount of clinical data required.
The totality of the data is what provides some confidence that
the drug has clinical activity. Investigators must be creative
and propose new biomarkers and clinical endpoints. Regula-
tors emphasise the importance of seeking scientific advice
when confronted with such dilemmas to ensure that studies
in small populations will provide sufficient evidence of safety
and efficacy. We should not lose sight that clinical benefit for
the patient is what counts at the end. If a biomarker is biolog-
ically plausible and if sufficient evidence is gathered, the
sponsor could certainly make a cogent argument for approval.
6. Making the leap from biomarker to
surrogate
To be a valid surrogate endpoint, a biomarker must accurately
predict a tangible clinical benefit, such as overall survival,
progression-free survival, or tumour response (RECIST).wer) of a patient with GIST with hepatic metastases. The
those on the right were done after 4 weeks of imatinib
metastases, a finding that is not substantiated in the MRI
morforschung), Essen, Germany.
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minimise the number of patients, as well as the time and re-
sources, required for pivotal studies. Identification of the bio-
marker and validation should not be attempted in the same
study; validation should be carried out in a separate popula-
tion. Also, from a regulatory standpoint, it is important to
avoid validating and then using the validated biomarker in
the same study to show treatment efficacy - a situation
termed circular validation. Such data would be very difficult
for regulators to accept as a basis for registration or licensure
of an agent. To avoid this, the sample size must be extended,
or the same population could be followed to reach a clinical
endpoint, such as overall survival. It is important to achieve
validation based on solid evidence that can be extrapolated
to clinical endpoints.
Survival is often held up as the gold standard of clinical
benefit, but might a ‘universal biomarker’ exist that would
be an indicator of benefit independent of the treatment? Such
a marker might correlate with the volume of viable tumour
cells or perhaps the number of tumour stem cells. Regulators
caution, however, that despite the commonly stated belief in
biomarkers as being the way of the future, only very few are
likely to be useful, true surrogates of clinical benefit. Never-
theless, if they are biologically plausible and substantiated
by data, biomarkers have an important role in conditional ap-
proval, and the sponsor can continue to collect data on clini-
cal endpoints.
The point of the conditional approval process is to make
drugs available to seriously ill patients as quickly as possible.
If problems become apparent during the post-marketing per-
iod, after conditional or accelerated approval, the drug can be
taken off the market. Compassionate use programs could al-
low patients who are experiencing some benefit to remain on
the treatment.
From a practical point of view, however, it might be diffi-
cult to withdraw a drug from the market if the conditions
for conditional approval were not met. Another factor to con-
sider is whether payers will cover the cost of conditionally ap-
proved agents.Ultimately, the goal of clinical trials is to gauge the benefit
to the patient, and the objective of conditional or accelerated
approval is to make promising treatments available to seri-
ously ill patients as quickly as possible – a near-impossible
task if a surrogate is not a valid means of predicting the effect
of treatment on the true endpoint. To be reasonably certain
that a treatment offers some benefit, one needs a fairly large
sample, replicable results, and an effect size. Validated mark-
ers are needed for estimating the true benefit and comparing
it with the risks.
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